Palvella Therapeutics’ (PVLA) “Buy” Rating Reaffirmed at BTIG Research

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a research note issued on Friday,Benzinga reports. They presently have a $192.00 price target on the stock. BTIG Research’s target price would indicate a potential upside of 88.24% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Craig Hallum started coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective for the company. Cantor Fitzgerald lifted their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. UBS Group reissued a “buy” rating and set a $143.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. Chardan Capital boosted their price objective on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Truist Financial increased their target price on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $158.69.

Palvella Therapeutics Price Performance

PVLA stock traded down $1.98 during mid-day trading on Friday, reaching $102.00. 74,446 shares of the company’s stock were exchanged, compared to its average volume of 197,158. The stock’s 50 day moving average is $95.63 and its 200 day moving average is $67.42. Palvella Therapeutics has a 12-month low of $12.10 and a 12-month high of $114.69. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -38.78 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, research analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Aspiriant LLC acquired a new stake in Palvella Therapeutics during the third quarter worth about $367,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after purchasing an additional 32,388 shares during the last quarter. Clio Asset Management LLC acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $2,063,000. XTX Topco Ltd bought a new stake in shares of Palvella Therapeutics in the 2nd quarter worth approximately $399,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth approximately $533,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.